The present invention provides Annexin A5 for use in a prophylactic or therapeutic method of preventing, reducing, delaying the onset of, or delaying the progression of, direct viral damage to the vascular system and/or immune system, in a subject, wherein the viral infection is caused by a virus selected from the group consisting of (a) a virus capable of causing hemorrhagic fever (VHF), and (b) a virus that presents phosphatidylserine (PS) and mediates cell infection and/or internalisation through PS binding.
